Boston Scientific, a biomedical/biotechnology engineering firm, completed the acquisition of a 65% stake in Acotec Scientific, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures, for $523m. "Acotec is a profitable, fast-growing company with a strong portfolio and innovative pipeline of medical technologies, and we believe this investment will generate growth opportunities for both companies. We expect completion of the partial offer to further strengthen our presence in China and create the potential for commercialization of Acotec products globally, providing an increased number of physicians and patients access to our robust and complementary product portfolios," Art Butcher, Boston Scientific Executive Vice President and Group President, MedSurg and Asia Pacific.